Enzyme

s/meetings/invited talks 1. Invited Speaker: Nomura DK (2023) Reimagining Druggability using Chemoproteomic Platforms. Japan Chemical Biology meeting, Osaka, Japan. 2. Invited Speaker: Nomura DK (2023) Reimagining Druggability using Chemoproteomic Platforms. Princeton University Department of Chemistry seminar series, Princeton, NJ. 3. Invited Speaker: Nomura DK (2023) Reimagining Druggability using Chemoproteomic Platforms. Hanson Wade Molecular Glue Degrader Summit, Boston, MA. 4. Invited Speaker: Nomura DK (2023) Reimagining Druggability using Chemoproteomic Platforms. Harvard Medical School Department of Cell Biology student invite, Boston, MA. 5. Invited Speaker: Nomura DK (2022) Reimagining Druggability using Chemoproteomic Platforms. University of Illinois, Urbana Champagne, 18th Annual CBI TP Symposium for the Chemistry-Biology Interface Training Program (CBITP), Urbana-Champagne, Illinois. 6. Invited Speaker: Nomura DK (2022) Reimagining Druggability using Chemoproteomic Platforms. FASEB Ubiquitin and Ubiquitin-like proteins conference, Boston, MA. 7. Invited Speaker: Nomura DK (2022) Reimagining Druggability using Chemoproteomic Platforms. Applied Pharmaceutical Chemistry Symposium, Cambridge, MA. 8. Invited Speaker: Nomura DK (2022) Reimagining Druggability using Chemoproteomic Platforms. 2nd Metabolism in Health and Disease, Cancun, Mexico. 9. Invited Speaker: Nomura DK (2022) Reimagining Druggability using Chemoproteomic Platforms. 2nd Induced Proximity-Based Drug Discovery Summit, Boston, MA. 10. Invited Speaker: Nomura DK (2022) Reimagining Druggability using Chemoproteomic Platforms. American Association of Cancer Research meeting, New Orleans, LA. 11. Invited Speaker: Nomura DK (2022) Reimagining Druggability using Chemoproteomic Platforms. UC Santa Cruz Department of Chemistry seminar series, Santa Cruz, CA. 12. Invited Speaker: Nomura DK (2022) Reimagining Druggability using Chemoproteomic Platforms. RSC Fragment based drug discovery, Cambridge, UK. 13. Invited Speaker: Nomura DK (2022) Reimagining Druggability using Chemoproteomic Platforms. University of Pennsylvania, Department of Chemistry, Virtual. 14. Invited Speaker: Nomura DK (2022) Reimagining Druggability using Chemoproteomic Platforms. Induced Proximity Targeting and Undruggables Conference, Boston, MA. 15. Invited Speaker: Nomura DK (2022) Reimagining Druggability using Chemoproteomic Platforms. Johns Hopkins University, Chemical Biology Interface Program student invite, Baltimore, Maryland. 16. Invited Speaker: Nomura DK (2021) Reimagining Druggability using Chemoproteomic Platforms. Pacific Chem Conference, Virtual. 17. Invited Speaker: Nomura DK (2021) Reimagining Druggability using Chemoproteomic Platforms. NYAS Targeted Protein Degradation: From Drug Discovery to the Clinic, Virtual 18. Invited Speaker: Nomura DK (2021) Reimagining Druggability using Chemoproteomic Platforms. Research seminar at Emory University, Atlanta, GA. 19. Invited Speaker: Nomura DK (2021) Reimagining Druggability using Chemoproteomic Platforms. Research seminar at University of Southern California, Los Angeles, CA. 20. Keynote Speaker: Nomura DK (2021) Reimagining Druggability using Chemoproteomic Platforms. International Chemical Biology Society meeting, Virtual 21. Invited Speaker: Nomura DK (2021) Reimagining Druggability using Chemoproteomic Platforms. LMU Munich Organic Chemistry seminar, Virtual 22. Invited Speaker: Nomura DK (2021) Reimagining Druggability using Chemoproteomic Platforms. Research seminar at UC Irvine, Irvine, CA. 23. Invited Speaker: Nomura DK (2021) Reimagining Druggability using Chemoproteomic Platforms. Research seminar at University of Minnesota, Minneapolis, Minnesota. 24. Invited Speaker: Nomura DK (2021) Reimagining Druggability using Chemoproteomic Platforms. Discovery on Target meeting, Cambridge, MA 25. Invited Speaker: Nomura DK (2021) Reimagining Druggability using Chemoproteomic Platforms. Novartis: Frontiers of Science and Medicine Institutional Lecture, Cambridge, MA 26. Invited Speaker: Nomura DK (2021) Reimagining Druggability using Chemoproteomic Platforms. Dana Farber Cancer Institute Chemical Biology Symposium, Virtual 27. Invited Speaker: Nomura DK (2021) Reimagining Druggability using Chemoproteomic Platforms. European Targeted Protein Degradation meeting, Virtual 28. Invited Speaker: Nomura DK (2021) Reimagining Druggability using Chemoproteomic Platforms. Vertex research seminar, Boston, MA 29. Invited Speaker: Nomura DK (2021) Reimagining Druggability using Chemoproteomic Platforms. Induced Proximity-Based Drug Discovery Summit, Hanson Wade, Virtual. 30. Invited Speaker: Nomura DK (2021) Reimagining Druggability using Chemoproteomic Platforms. BioTechne Symposium: Advances in Targeted Protein Degradation, Virtual 31. Invited Speaker: Nomura DK (2021) Reimagining Druggability using Chemoproteomic Platforms. Ligase Targeting Drug Development, Hanson Wade, Virtual. 32. Invited Speaker: Nomura DK (2021) Reimagining Druggability using Chemoproteomic Platforms. AACR meeting Chemistry in Cancer Research Town Hall, Virtual 33. Invited Speaker: Nomura DK (2021) Developing Coronavirus Anti-Viral Drugs. Center for Emerging and Neglected Diseases Symposium, Virtual. 34. Invited Speaker: Nomura DK (2021) Reimagining Druggability using Chemoproteomic Platforms. Helmholtz Drug Discovery Conference Speaker, Virtual. 35. Invited Speaker: Nomura DK (2021) Reimagining Druggability using Chemoproteomic Platforms. Rutgers University seminar speaker, Virtual. 36. Invited Speaker: Nomura DK (2021) Reimagining Druggability using Chemoproteomic Platforms. North American Protein Degradation Congress meeting, Kisaco Research, Virtual. 37. Invited Speaker: Nomura DK (2021) Reimagining Druggability using Chemoproteomic Platforms. Targeted Protein Degradation & PROTAC symposium, Oxford Global, Virtual. 38. Invited Speaker: Nomura DK (2021) Reimagining Druggability using Chemoproteomic Platforms. Stanford University, Department of Chemistry, Virtual. 39. Invited Speaker: Nomura DK (2021) Reimagining Druggability using Chemoproteomic Platforms. SLAS International Conference, Virtual. 40. Invited Speaker: Nomura DK (2020) Reimagining Druggability using Chemoproteomic Platforms. UCSF Cancer Center, Virtual. 41. Invited Speaker: Nomura DK (2020) Reimagining Druggability using Chemoproteomic Platforms. Dana Farber Cancer Center Targeted Protein Degradation Seminar Series, Virtual. 42. Invited Speaker: Nomura DK (2020) Reimagining Druggability using Chemoproteomic Platforms. Janssen, Virtual. 43. Invited Speaker: Nomura DK (2020) Reimagining Druggability using Chemoproteomic Platforms. Oregon Health Sciences University, Virtual. 44. Invited Speaker: Nomura DK (2020) Reimagining Druggability using Chemoproteomic Platforms. 3rd Annual Targeted Protein Degradation Meeting, Virtual. 45. Invited Speaker: Nomura DK (2020) Reimagining Druggability using Chemoproteomic Platforms. 18th Annual Discovery on Target Conference, Virtual. 46. Invited Speaker: Nomura DK (2020) Reimagining Druggability using Chemoproteomic Platforms. Northwestern University Department of Chemistry, Virtual. 47. Invited Speaker: Nomura DK (2020) Reimagining Druggability using Chemoproteomic Platforms. Pfizer, Virtual. 48. Invited Speaker: Nomura DK (2020) Reimagining Druggability using Chemoproteomic Platforms. Transcription Factor Drug Development Conference, Virtual. 49. Invited Speaker: Nomura DK (2020) Reimagining Druggability using Chemoproteomic Platforms. Seminar at Cygnal Therapeutics, Virtual. 50. Invited Speaker: Nomura DK (2020) Reimagining Druggability using Chemoproteomic Platforms. Natural Products Symposium at the New York Academy of Sciences, Virtual. 51. Invited Speaker: Nomura DK (2020) Reimagining Druggability using Chemoproteomic Platforms. North American Targeted Degradation Summit. San Diego, CA. 52. Invited Speaker: Nomura DK (2020) Reimagining Druggability using Chemoproteomic Platforms. The Mark Foundation for Cancer Research Induced Proximity Meeting, New York, New York 53. Invited Speaker: Nomura DK (2019) Reimagining Druggability using Chemoproteomic Platforms. MIT/Broad Institute Chemical Biology seminar series, Cambridge, MA 54. Invited Speaker: Nomura DK (2019) Reimagining Druggability using Chemoproteomic Platforms. Seminar at Calico, South San Francisco, CA 55. Invited Speaker: Nomura DK (2019) Reimagining Druggability using Chemoproteomic Platforms. California Institute of Technology Chemical Biology seminar series, Pasadena, CA 56. Invited Speaker: Nomura DK (2019) Reimagining Druggability using Chemoproteomic Platforms. UT San Antonio, San Antonio, TX. 57. Invited Speaker: Nomura DK (2019) Reimagining Druggability using Chemoproteomic Platforms. Harvard University Chemistry and Chemical Biology seminar speaker, Cambridge, MA 58. Invited Speaker: Nomura DK (2019) Reimagining Druggability using Chemoproteomic Platforms. Memorial Sloan Kettering Cancer Center, New York, NY. 59. Invited Speaker: Nomura DK (2019) Reimagining Druggability using Chemoproteomic Platforms. Bayer Life Science Workshop: Chemical Biology—Jointly Exploring New Frontiers, Berlin, Germany 60. Invited Speaker: Nomura DK (2019) Reimagining Druggability using Chemoproteomic Platforms. 2nd Targeted Protein Degradation Summit meeting, Boston, MA 61. Invited Speaker: Nomura DK (2019) Reimagining Druggability using Chemoproteomic Platforms. Northwestern University, Chicago, IL. 62. Invited Speaker: Nomura DK (2019) Reimagining Druggability using Chemoproteomic Platforms. American Chemical Society meeting, Targeted Protein Degradation session, San Diego, CA. 63. Invited Speaker: Nomura DK (2019) Reimagining Druggability using Chemoproteomic Platforms. Janssen Pharmaceuticals seminar speaker, Springhouse, Pennsylvania. 64. Invited Speaker: Nomura DK (2019) Reimagining Druggability using Chemoproteomic Platforms. Targeted Drug Discovery Summit, Boston, MA. 65. Invited Speaker:

[1]  D. Nomura,et al.  Reimagining Druggability Using Chemoproteomic Platforms. , 2021, Accounts of chemical research.

[2]  Daniel Nomura.  Redefining Druggability using Chemoproteomic Platforms , 2018 .

[3]  J. Casida,et al.  Lipases and their inhibitors in health and disease. , 2016, Chemico-biological interactions.

[4]  Jamie H. D. Cate,et al.  Bypassing the Pentose Phosphate Pathway: Towards Modular Utilization of Xylose , 2016, PloS one.

[5]  D. Nomura,et al.  GSTP1 Is a Driver of Triple-Negative Breast Cancer Cell Metabolism and Pathogenicity. , 2016, Cell chemical biology.

[6]  A. Paetau,et al.  Mitochondrial DNA Replication Defects Disturb Cellular dNTP Pools and Remodel One-Carbon Metabolism. , 2016, Cell metabolism.

[7]  D. Nomura,et al.  Mapping proteome-wide interactions of reactive chemicals using chemoproteomic platforms. , 2016, Current opinion in chemical biology.

[8]  A. Saghatelian,et al.  Editorial overview: Omics: The maturation of chemical biology. , 2016, Current opinion in chemical biology.

[9]  C. Skibola,et al.  The potential relevance of the endocannabinoid, 2-arachidonoylglycerol, in diffuse large B-cell lymphoma , 2016, Oncoscience.

[10]  K. Fisher,et al.  Mapping Proteome-Wide Targets of Environmental Chemicals Using Reactivity-Based Chemoproteomic Platforms. , 2015, Chemistry & biology.

[11]  A. Mai,et al.  Discovery of Inhibitors for the Ether Lipid-Generating Enzyme AGPS as Anti-Cancer Agents. , 2015, ACS chemical biology.

[12]  D. Nomura,et al.  Monoacylglycerol Lipase Regulates Fever Response , 2015, PloS one.

[13]  Melinda M. Mulvihill,et al.  Ski regulates Hippo and TAZ signaling to suppress breast cancer progression , 2015, Science Signaling.

[14]  Michael J. Park,et al.  Dependence of brown adipose tissue function on CD36-mediated coenzyme Q uptake. , 2015, Cell reports.

[15]  Melinda M. Mulvihill,et al.  Selective inhibitor of platelet-activating factor acetylhydrolases 1b2 and 1b3 that impairs cancer cell survival. , 2015, ACS chemical biology.

[16]  D. Nomura,et al.  Endocannabinoid Hydrolysis Generates Brain Prostaglandins That Promote Neuroinflammation , 2011, Science.

[17]  G. Siuzdak,et al.  The glycerophospho metabolome and its influence on amino acid homeostasis revealed by brain metabolomics of GDE1(-/-) mice. , 2010, Chemistry & biology.

[18]  D. Nomura,et al.  Monoacylglycerol Lipase Regulates a Fatty Acid Network that Promotes Cancer Pathogenesis , 2010, Cell.

[19]  D. Nomura,et al.  Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo , 2009, Proceedings of the National Academy of Sciences.

[20]  K. Fisher,et al.  Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. , 2008, Bioorganic & medicinal chemistry letters.

[21]  J. Casida,et al.  Organophosphate-sensitive lipases modulate brain lysophospholipids, ether lipids and endocannabinoids. , 2008, Chemico-biological interactions.

[22]  R. Krauss,et al.  Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins , 2008, Proceedings of the National Academy of Sciences.

[23]  J. Casida,et al.  Activation of the endocannabinoid system by organophosphorus nerve agents. , 2008, Nature chemical biology.

[24]  J. Casida,et al.  Dual roles of brain serine hydrolase KIAA1363 in ether lipid metabolism and organophosphate detoxification. , 2008, Toxicology and applied pharmacology.

[25]  Kathleen A. Durkin,et al.  Serine hydrolase KIAA1363: toxicological and structural features with emphasis on organophosphate interactions. , 2006, Chemical research in toxicology.

[26]  K. Fisher,et al.  Each lipase has a unique sensitivity profile for organophosphorus inhibitors. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[27]  J. Casida,et al.  A brain detoxifying enzyme for organophosphorus nerve poisons , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Casida,et al.  Toxicological and structural features of organophosphorus and organosulfur cannabinoid CB1 receptor ligands. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[29]  J. Casida,et al.  Arachidonylsulfonyl derivatives as cannabinoid CB1 receptor and fatty acid amide hydrolase inhibitors. , 2003, Bioorganic & medicinal chemistry letters.

[30]  J. Casida,et al.  Selective inhibitors of fatty acid amide hydrolase relative to neuropathy target esterase and acetylcholinesterase: toxicological implications. , 2002, Toxicology and applied pharmacology.

[31]  Sharon M. Louie.  Mapping Dysregulated Metabolic Pathways in Cancer Using Chemoproteomic and Metabolomic Platforms , 2017 .

[32]  Dan Nomura.  Abstract IA16: Mapping metabolic drivers of cancer using chemoproteomic and metabolomic platforms , 2016 .